Healthcare News

The first patient dosing has been completed in phase 3 clinical study of JS203 (CD20/CD3 bsAb), in combination with chemotherapy in patients with R/R DLBCL

>90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 12 weeks ~33-day half-life NAVIGATE-2 Phase 2 trial enrolling, with initial...

Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluated Additional data highlighted the challenges of managing...

Biochemist, entrepreneur and Just Blood founder Ryan El Hosseiny featured as “The Billboard Guy” in Nathan Fielder's documentary

SERB Pharmaceuticals announces positive results from the Post-Authorisation Efficacy Study (PAES) of Idefirix® (imlifidase),

Bei einer Zulassung wäre TALVEY® plus daratumumab bereits ab der Zweitlinie die einzige Kombinationstherapie mit bispezifischen, gegen GPRC5D gerichteten Antikörpern zur Behandlung des rezidivierten...

Sous réserve de son approbation, l’association TALVEY® et daratumumab constituerait la seule association thérapeutique comprenant un anticorps bispécifique ciblant le GPRC5D dans le traitement du...

Se approvata, la terapia a base di TALVEY® in combinazione con daratumumab sarà l'unica terapia combinata composta da un anticorpo bispecifico diretto contro GPRC5D per il mieloma multiplo recidivante...

Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all...

NeOnc (NASDAQ:NTHI) cleared several key resistance levels, on strong trading volume, an important technical signal before its upcoming catalysts